Reinmuth, N. Et Al. 2021. First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3 .

Reinmuth, N., Garassino, M. C., Trukhin, D., Hochmair, M. J., Ozguroglu, M., Havel, L., ... Goldman, J.(2021). First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.

Reinmuth, N. Et Al. "First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021

Reinmuth, N. Et Al. "First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021

Reinmuth, N. Et Al. (2021) . "First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.

@article{article, author={N. Reinmuth Et Al. }, title={First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2021}